Improving upper limb spasticity treatment with shock wave therapy and Botox.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of Extra-corporeal Shock Wave Therapy (ESWT) combined with Botulinum Toxin A (BoNTA) in treating upper limb spasticity compared to standard management. Conducted at the Glenrose Rehabilitation Hospital in Edmonton, Canada, the study will enroll participants with upper limb spasticity due to conditions like stroke or cerebral palsy. Participants will undergo a series of 10-11 visits for treatment and assessment, with data collected to evaluate the outcomes of the combined therapy. The goal is to determine if this innovative approach can enhance rehabilitation outcomes and reduce the burden of spasticity.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* People with upper limb Spasticity of Cerebral Origin, including but not limited to:
* Acquired brain injury (of at least 1 year following the event);
* Stroke;
* Cerebral Palsy (CP);
* Male and females over 18 years of age.
* Female subjects must either be post-menopausal, sterilized (at least 12 months post menses) or be consistently using a highly effective method of birth control such as a sterilized partner, oral/implanted/injected contraception or abstinence of sexual activity and be willing to provide a pregnancy test as the safe use of ESWT during pregnancy has not been demonstrated.
* Being naive to shockwave therapy;
* Spasticity as defined by Modified Ashworth Scale (MAS) score of 2 in a functional or non-functional upper limb affecting the target joint, which for the purpose of the study will be the elbow;
* Willingness to participate and provide written consent;
* Have the cognitive capacity to answers simple questionnaires;
* Either already receiving treatment with BoNTA and having been 'washed out' for a period of three months, or intends to begin 'standard treatment with BoNTA to an affected arm with target joint involvement.
* Standard treatment in the context of the study will include, in addition to any other therapies, focal treatment with Botulinum Neurotoxin Type A to treat the target joint.

Exclusion Criteria:

* Known neurodegenerative disorder at the spinal level;
* Known spinal cord lesion ;
* Fixed contracture of target joint impeding assessment or MAS of 4;
* Any demonstrated lower motor neuron damage to the affected limb;
* Surgery received to affected arm that may affect assessment of the target joint;
* Any changes in either oral or focally injected medications one month prior to screening to close out, that could influence any outcome measures;
* Any changes in medication one month prior to screening to close out, for the treatment of depression as changes in patient affect may influence outcome measures;
* Any changes in rehabilitation therapy throughout the study cycles;
* Confirmed pregnancy. Safe use in this population remains unknown;
* Nursing mothers. Safe use in this population remains unknown;
* Female patients who are of childbearing age without adequate contraception and unwilling to take a pregnancy test;
* Implanted electronic device/s. Kinetic energy in the same territory as an implanted device may adversely affect the device's function;
* Patients taking Warfarin and have poorly controlled coagulopathy or an INR above 3 at the Point of Care. To avoid hematoma, compartment syndrome or other consequences of prolonged bleeding to treated area. This is also the same program criteria for injection with BoNTA. For this population INR will be determined (using the Coguchek XL device) prior to each treatment;
* Any malignant diagnoses. Tissue disruption caused by the shockwave treatment may precipitate the liberation or shedding of cancer cells;
* Any known infection, inflammatory process, open areas or acute undiagnosed swelling (acute being defined as 14 days or sooner) in the area treated to avoid worsening of any pre-existing condition;
* Participation in any other concurrent study.

Where it's running

• Glenrose Rehabilitation Hospital
  Edmonton, Alberta, Canada Recruiting

Study contacts

• Principal investigator: Lalith E Satkunam, MD — Alberta University
• Study coordinator: Steacy Wray, RN
• Email: StaceyMWray@ahs.ca
• Phone: 780 735 8261

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Brain–spinal cord–muscle connectivity during selective dorsal rhizotomy in children with spasticity

  This project will record brain-to-spinal-cord-to-muscle signals during selective dorsal rhizotomy in children ages 3–17 with spasticity to see how the surgery changes nervous system connections.

  Recruiting at 2 sites Fondation Ophtalmologique Adolphe de Rothschild · Nice and 1 other locations · NCT06281223

• Effectiveness of the Mollii Suit for children with cerebral palsy

  This study is testing if the Mollii Suit can help children with spastic cerebral palsy improve their movement and reduce pain.

  Recruiting Kastamonu University · Ankara · NCT06109129

• Treatment for muscle tightness after stroke, spinal cord injury, or cerebral palsy

  This study is testing a new treatment using targeted radiation to see if it can help reduce muscle tightness in people who have had a stroke, spinal cord injury, or have cerebral palsy.

  Recruiting at 2 sites Ohio State University · Winter Park, Florida and 1 other locations · NCT06070233

• Measuring muscle characteristics in patients with cerebral palsy

  This study is testing a new way to measure muscle characteristics in people with cerebral palsy to see how muscle tightness and stiffness change as they get older, which could help improve treatment options.

  Recruiting at 3 sites Region Stockholm · Stockholm and 2 other locations · NCT05518565

• Gene therapy for treating SPG50 in children

  This study is testing a new gene therapy called MELPIDA to see if it can safely help children with Spastic Paraplegia Type 50 feel better and reduce their symptoms.

  Recruiting Phase 1/2 Elpida Therapeutics SPC · Dallas, Texas · NCT05518188

• Genetic analysis of hereditary spastic paraplegia

  This study is trying to find out the genetic causes of hereditary spastic paraplegia to help improve diagnosis and treatment for people living with this condition.

  Recruiting Boston Children's Hospital · Boston, Massachusetts · NCT05354622

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.